Almost the whole world is suffering from pandemic known as COVID-19 by one or the other way, irrespective of economic, technologic, weapon, political advantages they have. Homeopathic remedies have been used as prophylactic to prevent the epidemic since centuries. This site gives information on homeopathy in respect to COVID-19.

Tracing the history it was Hahnemann who first applied the genus epidemicus in 1799 during a scarlet fever epidemic he treated in the German town Königslutter. It is an interesting story that how how Dr. Hahnemann had accidentally discovered the genus epidemicus. A few members of large family with scarlet fever approached Dr. Hahnemann for treatment. He noticed that a child already under the doses Belladonna for other problem did not develop symptoms of scarlet fever. That was the moment he discovered Belladonna as a prophylactic for the entire family which he administered to all of them. Hahnemann concluded that a remedy that rapidly cures at the onset of an illness would be the best preventative.

Homeopathy was successfully applied during the epidemic of Spanish flu in 1918-19, where around 20 million people died globally. Mortality rate in homeopathic treated population was 1-2%, whereas it was 30-60% in people treated by conventional physicians. Chikungunya, dengue fever, acute encephalitis/japanese encephalitis, cholera and dengue were also successfully managed with homeopathy.

Recenlty Ministry of AYUSH, Government of India has published the recommendation of Expert Committee constituted by CCRH for the using of Arsenicum album 30CH as Genus epidemicus for prevention. Following that, many governments and autonomous bodies under different governments have used this as prophylactic. Apart from that, many other stalwarts have suggested possible role of other drugs in the current situation. A group of homeopaths from Italy have published an observational study of confirmed or suspected COVID-19 patients. None of the patients was required hospitalization.

This site contains database on homeoeopathy in respect to COVID-19.

Determining the safety, effects, and efficacy of Novus-CV in homoeopathic dilution in humans for Covid-19 disease prevention

Homoeopathic philosophy suggests nosodes can be used before, during, and after active cases for prevention and treatment. The human immunological response to severe acute respiratory syndrome Covid-19 disease expression can range from mild symptoms leading to resolution, to severe symptoms leading to complete system collapse, death, or prolonged post-disease conditions. The target of any disease prevention program starts with supporting immune system responses and reducing susceptibility. Homoeoprophylaxis (HP) with the Novus-CV nosode, aims to activate mild, disease specific, short-lived immune responses intended to facilitate the disease process and/or lessen the effects of, or susceptibility to, Covid-19 disease expression. The mild, shortlived immunological responses to the nosode are considered an important step in preventing disease. The collated nosode driven symptom presentation of new and/or resolved symptoms can serve as a reference guide to the homoeopathic indications for use of the nosode in active or unresolved cases.


Registration started March 13, 2020, prior to the initial peak of cases in the United State. Registrants undertook a self-administered dosing schedule of Novus-CV in various potencies. To establish safety, effects and efficacy of Novus-CV registrants of all age groups, from pregnant women and children to the elderly, registered a completed initial health profile, a two-week follow-up and a three-month follow-up. 

i. Safety was determined by assessing the types, duration, and degree of responses noted from the respondent. Also, by resultant changes, if any, in chronic health conditions. 

ii. Effects were overseen by registrants’ personal HP Supervisors and self-reported in online follow-up forms, and through verbal confirmation. These effects were considered proving and clinically curative effects and were collated by location, sensation, modalities, and extensions as per homoeopathic Materia Medica criteria. 

iii. Efficacy was evaluated for all respondents and specifically in those with definite exposure to either previous disease expression or active cases. 


A total of 1169 people of all age groups registered in the study. Of these 846 responded to follow-up. Peak dosing dates took place prior to the spring surge in cases. A total of 3181 administered doses were reported from 796 respondents during the two-week follow-up period. A total of 2741 symptoms and/or change in symptoms were reported in all organ systems. Of the 89 respondents with previous disease expression, of which 17 were unresolved, 16.5 recovered after nosode administration. Of the 62 respondents with active disease expression upon registration, there was a 96.77% resolution rate. Of the 135 with known exposure to individuals with previous or active disease, 56 developed short-lived mild proving symptoms of which 98.7% resolved by the end of the dosing period, none developed Covid-19-like disease. Of the total 434 three-month respondents zero developed Covid-19- like disease during the follow-up period indicating that the HP dosing was 100% effective in disease prevention. After dosing, 0.02% of individuals experienced aggravation of chronic conditions suggesting minimal long-term negative effects.   Not a single adverse event was reported. Sixty-eight of the 434 three-month follow-ups reported single or multiple PCR or antibody tests all had negative results. The catalogued Materia Medica demonstrated sustained evolution from active disease to resolution and fear and sickness to confidence and well-being through the follow-up period.

Conclusions: Regardless of age of participant or previous health condition, the Novus-CV nosode can be used before, during, or after demonstration of Covid-19 symptom expression, to prevent disease, mitigate active disease and resolve past disease. With no associated adverse events reported, these results suggest Novus-CV nosode offers the world a low-risk disease prevention method that is 100% effective in those with definite exposure that deserves consideration in public health programs. Covid-19-like disease’ is the term we are using for the compilation of symptoms registrants had or developed during the study period. As no comprehensive testing or official diagnosis process was undertaken, subjective reports of the registrants and respondents was used to evaluate if they had a symptom expression consistent with the CDC description of the disease. Adverse events as defined by the National Institute of Health guidelines for research on human subject is defined as a death, life-threatening adverse drug or device experience, inpatient hospitalisation or prolongation of existing hospitalisation, a persistent disability/incapacity, or a congenital anomaly/birth defect. Throughout the research the tenets of homoeopathy were verified. The symptoms produced and resolved after dosing corresponded with the active disease presentation and ranged from short-lived, mild fevers, cough, vomiting and diarrhea, and general malaise to feelings of well-being and increased vitality; activation of acute discharges and fevers brought forth wellbeing. This catalogued Materia Medica can be used as the indications for effective clinical prescribing; it also offers insight into the nature of susceptibility of Covid-19 as we evolve through this epidemic, the homoeopathic principles of like cures like and acute disease resolves chronic disease, and it supports the concept that the miasmatic root of disease may be accountable for contagion. Accordingly, with the positive health effects noted in those with active or unresolved disease, Novus-CV is effective to treat or as an adjunct to treatment in active and unresolved cases. 

Reference: Birch, K., et al. "Determining the safety, effects, and efficacy of Novus-CV in homoeopathic dilution in humans for Covid-19 disease prevention." The Australian Journal of Homoeopathic Medicine 34.5 (2021): 1.

Full text link:

Clinical Repurposing of Medicines is Intrinsic to Homeopathy: Research Initiatives on COVID-19 in India



As at mid-October 2020, the coronavirus disease 2019 (COVID-19) pandemic has been continuing on the rise across the globe, including in India. Historically, homeopathy has been used in a number of epidemics/pandemics. The development of homeopathic medicines is approached uniquely through “drug provings” and clinical verification; these two intrinsic processes establish the background for the application of homeopathic medicines, regardless of nosological diagnosis. This article reflects research initiatives on COVID-19 in India and identifies studies listed in the Clinical Trial Registry–India database. We identified 29 studies being undertaken in different settings, including those in conventional medicine: 20 randomized controlled trials (RCTs) and 9 observational studies. Fifteen studies are aimed at prophylaxis and 14 are aimed at treatment. Amongst the treatment studies, 11 are focused on efficacy or comparative effectiveness. The findings might provide evidence for clinically repurposing some of homeopathy's medicines, an approach that is intrinsic to the therapy, enabling their use in COVID-19 as an adjuvant or stand-alone to help reduce costs and improve patient recovery.

Reference: Varanasi, Roja, Debadatta Nayak, and Anil Khurana. "Clinical repurposing of medicines is intrinsic to homeopathy: research initiatives on COVID-19 in India." Homeopathy 110.03 (2021): 198-205.

Randomized Double-Blind, Placebo-Controlled Feasibility Study, Evaluating the Efficacy of Homeopathic Medicines in the Prevention of COVID-19 in a Quarantined Population



Introduction Exploring preventive therapeutic measures has been among the biggest challenges during the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We explored the feasibility and methods of recruitment, retention, and potential signal of efficacy, of selected homeopathic medicines as preventive measure for developing COVID-19 in a multi-group study.

Methods A six-group, randomized, double-blind, placebo-controlled prophylaxis study was conducted in a COVID-19 exposed population in a quarantine facility in Mumbai, India. Each group received one of the following: Arsenicum album 30c, Bryonia alba 30c, a combination (Arsenicum album 30c, Bryonia alba 30c, Gelsemium sempervirens 30c, and Influenzinum 30c), coronavirus nosode CVN01 30c, Camphora 1M, or placebo. Six pills twice a day were administered for 3 days. The primary outcome measure used was testing recruitment and retention in this quarantined setting. Secondary outcomes were numbers testing positive for COVID-19 after developing symptoms of illness, number of subjects hospitalized, and days to recovery.

Results Good rates of recruitment and retention were achieved. Of 4,497 quarantined individuals, 2,343 sought enrollment, with 2,294 enrolled and 2,233 completing the trial (49.7% recruitment, 97.3% retention). Subjects who were randomized to either Bryonia alba or to the CVN01 nosode signaled (p <0.10) a lower incidence of laboratory-confirmed COVID-19 and a shorter period of illness, with evidence of fewer hospitalizations, than those taking placebo. The three other groups did not show signals of efficacy.

Conclusion This pilot study supports the feasibility of a larger randomized, double-blind, placebo-controlled trial. Bryonia alba 30c and CVN01 30c should both be explored in disease prevention or shortening the course of disease symptomatology in a COVID-19-exposed population.

Reference: Talele, Gitanjali, et al. "Randomized double-blind, placebo-controlled feasibility study, evaluating the efficacy of homeopathic medicines in the prevention of COVID-19 in a quarantined population." Homeopathy 111.01 (2022): 049-056.

Preparation of Coronavirus nosodes sourced from a clinical sample of SARS-Cov-2 positive patient, inactivated strain, and spike glycoprotein


Nosodes, the homeopathic preparations sourced from biological materials including clinical samples, cultures of organisms, and diseased tissues have been in use against the source-specific infections as well as other diseases. The nosodes have demonstrated some efficacy in managing epidemics, such as influenza, dengue, and leptospirosis. This article presents the need and process of development of nosodes from the SARS-CoV-2 to explore its prophylactic and therapeutic potentials against certain related viral diseases. 
A clinical sample of SARS-Cov-2 positive patient, based on the cycle threshold (CT) value of the qRT-PCR, heat-inactivated SARS-CoV-2, and spike glycoprotein all were processed for making nosodes as per the method described in Homoeopathy Pharmacopoeia of India. Molecular tests, such as qRT- PCR and sterility tests were performed to establish the live organisms, RNA material, and the absence of contamination. 
Three variants of Coronavirus Nosode were developed using a clinical sample, heat-inactivated SARS-CoV-2, and spike glycoprotein. In potencies 3c and above, no detectable SARS-CoV-2 RNA material was found by PCR. The analytical results for nosodes were reported as compliant for sterility testing as per the IP. 
Three variants of Coronavirus nosodes were prepared which need to be evaluated further through pre-clinical and clinical studies.

Reference: Mukherjee, Sandeepan, et al. "Preparation of Coronavirus nosodes sourced from a clinical sample of SARS-Cov-2 positive patient, inactivated strain, and spike glycoprotein: Coronavirus Nosode article." International Journal of High Dilution Research-ISSN 1982-6206 19.4 (2020): 02-09.

Full text pdf link:https://www.highdilution.org/index.php/ijhdr/article/view/1054/1061 

An open-label, exploratory documentation of proving-symptoms of CVN01 (Coronavirus nosode from the clinical sample) in healthy volunteers


INTRODUCTION Homeopathic Pathogenetic Trials (Proving) are human studies to examine the pathogenetic effects of investigational drugs in high dilution on healthy volunteers. As a part of the new coronavirus nosode development process for prophylactic use, the phase 1 study was conducted. The documentation of proving symptoms for a fast-track nosode development for a pandemic condition was the objectives of this study. MATERIALS AND METHODS An open-label trial to evaluate the safety and proving symptoms of Coronavirus nosode given orally to 10 volunteers (18-65 years age and of both the genders). Volunteers were administered 6 doses of nosode as 6 pills twice daily for 3 consecutive days. Pre and post examinations (physical), vital signs, and laboratory investigations, were done at day 0, 17, 34. Symptoms experienced by the volunteers were recorded. RESULTS Symptoms reported by volunteers were analyzed. The symptoms reported were mild to severe but reversible and matching with the symptoms produced by the viral infection. There were no serious/fatal adverse events during the study. The basic biochemistry and Liver Function tests were not affected by the Nosode. CONCLUSION New nosode developed during a pandemic condition produced certain symptoms in the homeopathic pathogenetic trial as a part of the Phase 1 study.

Reference: Shah, Rajesh, and Gitanjali Talele. "An open-label, exploratory documentation of proving-symptoms of CVN01 (Coronavirus nosode from the clinical sample) in healthy volunteers: Drug proving symptoms of Coronavirus nosode." International Journal of High Dilution Research-ISSN 1982-6206 20.2-3 (2021): 44-50. 

Source: https://www.highdilution.org/index.php/ijhdr/article/view/1073

Full text pdf: https://www.highdilution.org/index.php/ijhdr/article/view/1073/1079

Homeopathic Remedies in COVID-19: Prognostic Factor Research


1Health and Family Welfare Department, Directorate of AYUSH, Government of National Capital Territory of Delhi, New Delhi, India.


Background/objective: Coronavirus disease 2019 (COVID-19) is a new disease; its clinical profile and natural history are evolving. Each well-recorded case in homeopathic practice is important for deciding the future course of action. This study aims at identifying clinically useful homeopathic remedies and their prescribing symptoms using the prognostic factor research model.

Methods: This was an open-label, multi-centric, observational study performed from April 2020 to July 2020 at various public health care clinics. The data were collected prospectively from clinical practice at integrated COVID-19 care facilities in India. Good-quality cases were selected using a specific set of criteria. These cases were analyzed for elucidating prognostic factors by calculating the likelihood ratio (LR) of each frequently occurring symptom. The symptoms with high LR values (>1) were considered as prescribing indications of the specific remedy.

Results: Out of 327 COVID-19 cases reported, 211 met the selection criteria for analysis. The most common complaints were fatigue, sore throat, dry cough, myalgia, fever, dry mouth and throat, increased thirst, headache, decreased appetite, anxiety, and altered taste. Twenty-seven remedies were prescribed and four of them-Arsenicum album, Bryonia alba, Gelsemium sempervirens, and Pulsatilla nigricans-were the most frequently used. A high LR was obtained for certain symptoms, which enabled differentiation between the remedies for a given patient.

Conclusion: Homeopathic medicines were associated with improvement in symptoms of COVID-19 cases. Characteristic symptoms of four frequently indicated remedies have been identified using prognostic factor research, findings that can contribute to accurate homeopathic prescribing during future controlled research in COVID-19.

Reference: Manchanda RK, Miglani A, Gupta M, Meena BS, Chadha V, Joseph F, Kalsi A, Konthembath P, Sharma K, Rama KN, Kaur P, Thavarayil Kannoth J, Nagrath C, Jethani A, Nellikka Aniyeri S, Chawla A, Ray MK, Ghuliani M, Kudiyarasu RK, Naskar S, Bala S, Sharma B. Homeopathic Remedies in COVID-19: Prognostic Factor Research. Homeopathy. 2021 Aug;110(3):160-167. doi: 10.1055/s-0041-1725989. Epub 2021 Apr 30. PMID: 33930904.

PubMed link: https://pubmed.ncbi.nlm.nih.gov/33930904

Homeopathic Treatment for COVID-19-Related Symptoms: A Case Series

Kurd R(a), Freed Y(b), Jarjoui A(c), Izbicki G(c), Levin P(d), Helvitz Y(d), Sherr J(e), Oberbaum M(b)

Author affiliations
(a)Internal Medicine Division, Shaare Zedek Medical Center, Jerusalem, Israel 
(b)Center for Integrative Complementary Medicine, Shaare Zedek Medical Center, Jerusalem, Israel 
(c)Pulmonary Institute, Shaare Zedek Medical Center, Jerusalem, Israel 
(d)Intensive Care Unit, Shaare Zedek Medical Center, Jerusalem, Israel 
(e)Dynamis, London, United Kingdom 

Background: Severe acute respiratory syndrome due to coronavirus 2 (SARS CoV-2) is a novel infectious disease, which has quickly developed into a pandemic. The spectrum of COVID-19 symptoms is broad, ranging from a mild, self-limiting respiratory tract illness to severe progressive pneumonia, multi-organ failure and possible death. Despite much effort and multiple clinical trials, there are, to date, no specific therapeutic agents to treat or cure the coronavirus infection. Case Reports: The present paper presents 5 cases of patients with moderate to severe COVID-19 infections, 2 of them hospitalized in the intensive care unit, who were successfully treated with homeopathy. Results: All 5 patients responded to homeopathic treatment in an unexpectedly short time span, improving both physically and mentally. Conclusion: The present case series emphasizes the rapidity of response among moderate to severely ill patients to homeopathic treatment, when conventional medical options have been unable to relieve or shorten the disease. The observations described should encourage use of homeopathy in treating patients with COVID-19 during the acute phase of the disease.

Reference: Kurd, Ramzi, et al. "Homeopathic Treatment for COVID-19-Related Symptoms: A Case Series." Complementary Medicine Research 29.1 (2022): 83-88.

Revised Guidelines for Homoeopathy Practitioners for Prophylaxis and Symptomatic Management of Home IsolatedCOVID-19 Patients

Ministry of AYUSH, Government of India has published Revised Guidelines for Homoeopathy Practitioners for Prophylaxis and Symptomatic Management of Home IsolatedCOVID-19 Patients.